Skip to main content

Table 4 Antimicrobial susceptibility pattern of S. aureus and MRSA from patients with surgical site infection at Debre Markos Referral Hospital, Amhara, Ethiopia [December, 2011 - March, 2012]

From: Isolation and antimicrobial susceptibility pattern of Staphylococcus aureus in patients with surgical site infection at Debre Markos Referral Hospital, Amhara Region, Ethiopia

 

S. aureus (n = 73)

MRSA (n = 36)

Antimicrobial agent

Sensitive no. (%)

Intermediate no. (%)

Resistant no. (%)

Sensitive no. (%)

Intermediate no. (%)

Resistant no (%)

Ampicillina

13 (17.8)

-

60 (82.2)

-

-

36 (100)

Amoxicillina

13 (17.8)

-

60 (82.2)

-

-

36 (100)

Erythromycina

-

3 (4.1)

70 (95.9)

-

1 (2.8)

35 (97.2)

Gentamicina

9 (12.3)

-

64 (87.7)

2 (5.6)

-

34 (94.4)

Tetracyclinea

37 (50.7)

12 (16.4)

24 (32.9)

12 (33.3)

9 (25)

15 (41.7)

Penicillin Ga

13 (17.8)

-

60 (82.2)

-

-

36 (100)

Clindamycina

7 (9.6)

31 (42.4)

35 (47.9)

2 (5.6)

12 (33.3)

22 (61.1)

Cotrimoxazolea

1 (1.4)

1 (1.4)

71 (97.2)

-

-

36 (100)

Vancomycina

70 (95.9)

-

3 (4.1)

34 (94.4)

-

2 (5.6)

Oxacillina

37 (50.7)

-

36 (49.3)

-

-

36 (100)

  1. aClinical and Laboratory Standards Institute (CLSI) breakpoint for Staphylococcus spp.
  2. AMP: ampicillin, AML: amoxicillin, P: penicillin G, CN: gentamicin, E: erythromycin, Ox: oxacillin, TE: tetracycline, DA: clindamycin, SXT: cotrimoxazole, VA: vancomycin.
  3. Intermediate resistant: The “intermediate” category includes isolates with antimicrobial MICs that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates (CLSI definition).